ESR1 and breast cancer: Despite evidence indicating the importance of this pathway in multiple aspects of breast cancer pathogenesis, the only inhibitors of this pathway in clinical use are the PI3K inhibitor, alpelisib, in PI3K-mutant tumors, and the rapalog everolimus, both approved for use in hormone therapy refractory estrogen receptor positive (ER+) breast cancers.